Category:Cancer treatments
From WikiMD's Wellness Encyclopedia
 | Pages in this category should be moved to subcategories where applicable. This category may require frequent maintenance to avoid becoming too large. It should directly contain very few, if any, pages and should mainly contain subcategories. |
Subcategories
This category has the following 2 subcategories, out of 2 total.
Pages in category "Cancer treatments"
The following 200 pages are in this category, out of 586 total.
(previous page) (next page)A
- Abituzumab
- Abstral
- ABT-510
- Active immunotherapy
- Active surveillance
- ACY-1215
- ADE (chemotherapy)
- Adecatumumab
- Adegramotide
- ADEPT
- ADH-1
- Adjuvant therapy
- Adjuvant chemotherapy
- Adoptive cell therapy
- Adoptive cell transfer
- Adoptive immunotherapy
- ADXS11-001
- AFP-07
- Aldesleukin
- ALK inhibitor
- Alkylating antineoplastic agents
- Alpelisib
- Alpha-interferon
- ALT-803
- Alternating electric field therapy
- Altumomab pentetate
- Amatuximab
- AMG 319
- Amphinex
- ANG1005
- Angiostatin
- Annamycin
- Anti-cancer medication
- Anti-CTLA-4
- Anti-idiotypic vaccine
- Anti-VEGF
- Antiangiogenesis
- Antiangiogenic
- Antibody-drug conjugate
- Antibody-drug conjugates
- Antibody–drug conjugate
- Antihormone therapy
- Template:Antineoplastic-agents-stub
- Antineoplastics
- Apatinib
- Aromatase Inhibitor
- Artificial fever
- Asparaginase erwinia chrysanthemi
- Atrasentan
- Auger therapy
- Autologous immune enhancement therapy
- Autologous tumor cell
- Avapritinib
- Avicine
- Axicabtagene ciloleucel
B
- Bavituximab
- Belantamab mafodotin
- Belvarafenib
- Bempegaldesleukin
- Berzosertib
- BI 811283
- Bi-specific T-cell engager
- Binimetinib
- Biologic Response Modifiers
- Bivatuzumab
- Bivatuzumab mertansine
- Bland embolization
- Boron neutron capture therapeutics
- Brachytherapy
- BRAF inhibitor
- Brexucabtagene autoleucel
- Brigatinib
- Brivanib alaninate
- Brontictuzumab
C
- C-1027
- C-Met inhibitors
- Camidanlumab tesirine
- Cancer Chemotherapy and Pharmacology
- Cancer drugs
- Cancer therapy
- Cancer Treatment
- Cantuzumab
- Capmatinib
- Capsaicin
- CAR T cell
- CAR T-cell therapy
- Carmustine
- Carmustine implant
- Catumaxomab
- Cellular adoptive immunotherapy
- Chemo
- Chemoimmunotherapy
- Chemoradiation
- Chemosensitizer
- Chemotherapeutic
- Chemotherapy
- Chemotherapy drug
- Chemotherapy medication
- Chimeric antigen receptor
- Chimeric antigen receptor T cell
- CHR-3996
- Cirmtuzumab
- Cisplatin
- Citatuzumab
- Citatuzumab bogatox
- Cixutumumab
- Clevegen
- Clostridium novyi-NT
- Cofetuzumab pelidotin
- Coley's toxins
- Combination chemotherapy
- Combinatorial ablation and immunotherapy
- Combined photothermal and photodynamic therapy
- Complete response
- Conatumumab
- Conization
- Continuous hyperthermic peritoneal perfusion
- Cross-firing
- Cryoimmunotherapy
- Cryosurgery
- Custirsen
- Cyberknife (device)
- Cytarabine
- Cytokine therapy
- Cytostatic
- Cytostatics
D
- Dabrafenib
- Dacarbazine
- Dacetuzumab
- Dactolisib
- Dalantercept
- Dalotuzumab
- DAT (chemotherapy)
- Debulking
- Defactinib
- Demcizumab
- Dendritic cell-based cancer vaccine
- Depatuxizumab
- Detumomab
- Devimistat
- Dinutuximab beta
- Discovery and development of tubulin inhibitors
- Donor lymphocyte infusion
- Dose-dense chemotherapy
- Duligotumab
- Dusigitumab
E
- EBC-46
- Ecromeximab
- Edodekin alfa
- Edrecolomab
- Electrochemotherapy
- Emtansine
- Enavatuzumab
- Encorafenib
- Endocrine therapy
- Endoscopic mucosal resection
- Endostatin
- Engineered CAR T cell delivery
- Enoblituzumab
- Ensituximab
- Erlizumab
- Ertumaxomab
- Estrogen deprivation therapy
- Etoposide
- Etoposide phosphate
- Exagamglogene autotemcel
- Exherin
- Extracorporeal photopheresis
